Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed malignant glioma of 1 of the following subtypes:
• •* Low-grade glioma
• •* Anaplastic astrocytoma
• •* Anaplastic oligodendroglioma
• •* Glioblastoma multiforme
• •Unifocal disease that is progressive or recurrent after prior radiotherapy and/or chemotherapy
• •Scheduled to undergo surgical resection
• •* Able to undergo maximal surgical resection of tumor mass
• •PATIENT CHARACTERISTICS:
• •Karnofsky performance status 70-100%
• •Mini Mental Status Exam ≥ 15
• •Absolute neutrophil count ≥ 1,500/mm³
• •Platelet count ≥ 100,000/mm³
• •Creatinine ≥ 1.7 mg/dL
• •BUN ≤ 2 times upper limit of normal (ULN)
• •Transaminases ≤ 4 times ULN
• •Not pregnant or nursing
• •Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment
• •No other medical illness that would preclude study treatment, including any of the following:
• •* Serious infection
• •* Uncontrolled hypertension
• •* Unstable angina pectoris
• •* Uncontrolled cardiac dysrhythmia
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •Recovered from all prior therapy
• •At least 4 weeks since prior investigational drugs
• •No more than 1 prior chemotherapy regimen
• •No concurrent chemotherapy, biologic therapy, or radiotherapy
• •No concurrent medications that may interact with imatinib mesylate or interfere with hepatic cytochrome P450 system